Anavex Life Sciences
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -6,782 | -6,485 | -14,307 | -12,417 |
EBIT | -11,292 | |||
Net Income | -5,681 | -9,827 | -13,243 | -11,196 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,151 | -8,604 | -12,464 | -5,856 |
Cash | 131,749 | 102,577 | 101,164 | 115,771 |
Basic Shares | 89,029 | 85,893 | 85,380 | 85,073 |
Annual Financials
| Values in thousands | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -46,377 | -43,002 | -47,498 | -47,620 |
EBIT | -45,293 | -47,498 | -47,619 | |
Net Income | -46,377 | -43,002 | -47,491 | -47,978 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,949 | |||
Free Cash Flow | -39,044 | -30,812 | -27,785 | -24,238 |
Cash | 102,577 | 132,187 | 151,024 | 149,157 |
Basic Shares | 85,289 | 83,468 | 79,788 | 76,910 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.06 |
2025-09-30 | -$0.11 |
2025-06-30 | -$0.16 |
